Following the FDA approval of a pneumococcal 15-valent conjugate vaccine (Vaxneuvance) for the prevention of invasive disease caused by Streptococcus pneumoniae in children, we were delighted to speak with Dr. Steven Shapiro (Jefferson Abington Hospital, Abington, PA, USA) to discuss the unmet needs, the clinical data supporting the approval, and the impact approval will have on preventing invasive pneumococcal disease.
Questions
- What are the unmet needs in the treatment of invasive pneumococcal disease in children? (0:30)
- Could you tell us a little about the pneumococcal 15-valent conjugate vaccine and in whom it is indicated? (1:07)
- What clinical data supported this FDA approval? (1:37)
- What adverse reactions are associated with the vaccine? (2:36)
- How can this vaccine be incorporated into paediatric vaccination programs and what will be its impact? (4:30)
Disclosures: Steven Shapiro has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
